Electronic Supplementary Material (ESI) for ChemComm. This journal is © The Royal Society of Chemistry 2018

Electronic Supplementary Information

Live-Cell Imaging of Multiple Endogenous mRNAs Permits Direct Observation of RNA Granule Dynamics

Kenji Yatsuzuka,^a Shin-ichi Sato,^{*a} Kathleen Beverly Pe,^a Yousuke Katsuda,^{‡a}

Ippei Takashima,^a Mizuki Watanabe §^a and Motonari Uesugi *^{ab}

^aInstitute for Chemical Research and ^bInstitute for Integrated Cell-Material Sciences (WPI-iCeMS), Kyoto University, Uji, Kyoto 611-0011, Japan

Present Addresses

‡Division of Materials Science, Faculty of Advanced Science and Technology, Kumamoto University, Kumamoto 860-8555, Japan
§Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan

*Correspondence should be addressed to M.U. (uesugi@scl.kyoto-u.ac.jp), and S.S. (ssato@scl.kyoto-u.ac.jp).

Supplementary Contents

Supplementary Figures	
Figure S1	S-3
Figure S2	S-4
Figure S3	S-5
Figure S4	S-6
Figure S5	S-7
Figure S6	S-8
Figure S7	S-9
Figure S8	S-10
Figure S9	S-11
Figure S10	S-12
Figure S11	S-13
Figure S12	S-14
Figure S13	S-15
Figure S14	S-16
Supplementary Tables	
Table S1	S-17
Table S2	S-18
Table S3	S-19
Table S4	S-20
Supplementary Videos	S-22
Supplementary Methods	
Chemical Synthesis	S-24
General procedures	S-35
Fluorescence measurement	S-35
In vitro selection procedures for DNB binding aptamer	S-36
Kd determination	S-36
Cell culture and DNA transfection	S-36
Fixed cell imaging	S-37
Live-cell imaging	S-37
References	S-38
NMR spectra	S-39

Supplementary Figures




Figure S1. Chemical properties of probe **1**. (A) Chemical structure of probe **1**. (B) Absorption spectra of BHQ1, sulfoCy3, a 1:1 mixture of BHQ1 and sulfoCy3, and BHQ1-sulfoCy3 conjugate probe **1** [5 μ M each] in a binding buffer (10 mM Tris-HCl, 100 mM KCl, 5 mM MgCl₂, pH 7.6). (C) Absorption spectra of probe **1** [5 μ M] in the presence of various concentrations of A1 aptamer.




Figure S2. NOESY analysis of probe **1**. (A,B) Expanded aromatic regions of NOESY spectra of probe **1** in DMSO- d_6 (A) and in 50% (v/v) D₂O/DMSO- d_6 (B); (C) Expanded aromatic to aliphatic regions of NOESY spectra of probe **1** in 50% (v/v) D₂O/DMSO- d_6 ; (D,E) Observed NOE interactions between BHQ1 and sulfoCy3 in DMSO- d_6 (D) and in 50% (v/v) D₂O/DMSO- d_6 (E). Blue arrows and red arrows indicate locations of weak and strong NOEs, respectively.




Figure S3. Absorption spectrum of BHQ1. Absorption spectra of BHQ1 [10 μ M] in the absence (black) and presence (red) of A1 aptamer [30 μ M] in binding buffer (10 mM Tris-HCl, 100 mM KCl, 5 mM MgCl₂, pH 7.6).




Figure S4. Full size (left) and enlargement (right) of fluorescence emission spectra of the probe **1** with (red) and without (black) the A1 aptamer, and sulfoCy3 (green) in binding buffer (10 mM Tris-HCl, 100 mM KCl, 5 mM MgCl₂, pH 7.6).




Figure S5. Fluorescence emission spectra of BHQ1-sulfoCy3 conjugate probes. (A) Fluorescence intensity of the probes $[2 \ \mu\text{M}]$ with different linker lengths, in the absence (black) and presence (red) of an A1 aptamer $[30 \ \mu\text{M}]$ in binding buffer (10 mM Tris-HCl, 100 mM KCl, 5 mM MgCl₂, pH 7.6). (B) Fluorescence intensity of each probe in quenched and fluorescent states.




Figure S6. Probe **5**. (A) Chemical structure of BHQ1-sulfoCy5 conjugate probe **5**. (B) Fluorescence emission spectra of the probe in the absence (black) and presence (red) of A1 aptamer.




Figure S7. *In vitro* selection of DNB aptamer. To obtain an RNA aptamer for DNB, we carried out in vitro selection of an RNA library comprising 60-base random sequences. The sequences that potentially exhibit cross-responses to BHQ1 were removed from the library using BHQ1-immobilized resins (steps 1 and 2). The unbound RNAs were further treated with DNB-immobilized resins (step 3). After extensive washing, DNB-binding sequences were eluted with free DNB (step 4). The next-generation library of the collected RNAs was regenerated by subsequent reverse transcription, polymerase chain reaction, and transcription (step 5).




Figure S8. DNB aptamers. (A) Converged sequences from in vitro selection for DNB-binding aptamers (DNB1-4). (B) Fluorescence emission spectra of probe **6** in the presence of each DNB aptamer. (C) Fluorescence intensity changes following binding of clones DNB1–4 to probe **6** and *K*d value of each aptamer. Relative fluorescence intensity is means \pm SD of at least three independent experiments.




Figure S9. Restoration of the fluorescence ability of DNB-RT aptamers. Fluorescence intensity of probe **6** with each aptamer in the absence and presence of the target RNA.




Figure S10. Probe **7**. (A) Chemical structure of DNB-DY conjugate probe **7**. (B) Fluorescence emission spectra of probe **7** in the absence (black) and presence (red) of the DNB1 aptamer.




Figure S11. Estimation of the cross response of aptamers to fluorescent probes. (A) Cross response of probe **7** to each aptamer. (B) Cross response of probe **5** to each aptamer. A1 aptamer and DNB1 aptamer have no cross response to the BHQ1-conjugated probe (**5**) and the DNB-conjugated probe (**7**), respectively.





Figure S12. Multicolor imaging of endogenous β -actin mRNA and cortactin mRNA in fixed HeLa cells. (A) Schematic illustration of the experiments. (B) Real experimental images. (a) Both probe **5** (red dots) and probe **7** (green dots) were targeted to β -actin mRNA by their corresponding aptamers; (b, c) probe **5** (red dots) and probe **7** (green dots) were targeted to different mRNAs; (d) both probe **5** (red dots) and probe **7** (green dots) were targeted to cortactin mRNA. (e) A control experimental image. Cells were treated with probe **5** and probe **7** and without aptamers. Staining of the nuclei with DAPI is shown in blue. (C) Assessment of colocalization between green and red fluorescent dots. Pearson's correlation coefficient values (Pearson's R) were quantified by ImageJ.



Pearson's R : 0.83

Pearson's R : 0.11

Figure S13. Multicolor imaging of endogenous mRNAs in living HeLa cells. (A) β -actin mRNA with BHQ1 aptamer paired with BHQ1-Cy5 probe **8** (red dots), and DNB aptamer paired with DNB-DY probe **7** (green dots). (B) β -actin mRNA with BHQ1 aptamer paired with BHQ1-Cy5 probe **8** (red dots); cortactin mRNA with DNB aptamer paired with DNB-DY probe **7** (green dots). (C) Background fluorescence of BHQ1-Cy5 probe **8** (red dots) and DNB-DY probe **7** (green dots) without aptamer expression. Staining of the nuclei with Hoechst 33342 is shown in blue. Co-localisation between BHQ1-Cy5 probe **8** (red dots) and DNB-DY probe **7** was quantified by ImageJ. Pearson's correlation coefficient values (Pearson's R) are shown at the bottom.

aptamer	aptamer sequences	target sequences
BHQ aptamar for β -Actin	GGAGCAAUGAUGGCCUAGAUAAAUUCGGUGCUUGAUCUUCAUU	AAUGAAGAUCAAGAUCAUUGCUCC
DNB aptamar for $\beta\text{-}Actin$	AUAGGAAUCCUACCGUCGACGUGCGGUGCUGUGACGCACUUGCAAUGUGGUUGACCCAUGCC	GGCAUGGGUCAGAAGGAUUCCTAU
BHQ aptamar for cortactin	UACUGUCUUCUGGCCUAGAUAAAUUCGGAGCUUAGGCAGAGGA	UCCUCUGCCUACCAGAAGACAGUA
DNB aptamar for cortactin	AAGGAUGAUGUACCGUCGACGUGCGGUGCTGUGACGCACUUGCAAUGUGGUUAAUGCACCUC	GAGGUGCAUUUUCUCAUCAUCCUU

β-Actin mRNA

accgccgagaccgcguccgccccgcgagcacagagccucgccuugccgauccgccgcccguccacacccgccgccgccagcucaccauggaugaugauaucg gcaccagggcgugauggug**GGCAUGGGUCAGAAGGAUUCCUAU**gugggcgacgaggcccagagcaagagggcauccucacccugaaguaccccaucgag cacggcaucgucaccaacuggggacgacauggagaaaaucuggcaccacaccuucuacaaugagcugcguguggcucccgaggagcaccccgugcugcuga ccdaddccccccndaacccccaaddccaaccdcdadaadandaccccadancandnnndadaccnncaacaccccadccandnacdnndcnanccaddcndn qcuaucccuquacqccucuqqccquaccacuqqcaucquqauqqacuccqquqacqqqqucacccacacuquqcccaucuacqaqqqquauqcccuccc ddasancdndcdndacannaaddadaadcndndcnacdncdcccnddacnncdadcaadadanddccscddcndcnnccadcnccncccnddadaadad ggcauccacgaaacuaccuucaacuccaucaugaagugugacguggacauccgcaaagaccuguacgccaacacagugcugucuggcggcaccaccaugu acccuggcauugccgacaggaugcagaaggagaucacugcccuggcacccagcacAAUGAAGAUCAAGAUCAUUGCUCCuccugagcgcaaguacuccgu aaaugcuucuaggcggacuaugacuuaguugcguuacacccuuucuugacaaaaccuaacuugcgcagaaaacaagaugagauuggcauggcuuuauuug nnnnnnndnnnndannnnddnnnnnnnnnnnddenndaeneaddannnaaaaeciddaaecddndaeadeadreddradeddadeaac ccccaaaguucacaauguggccgaggacuuugauugcacauuguuguuuuuuuaauagucauuccaaauaugagaugcguuguuacaggaagucccuugc cauccuaaaagccaccccacuucucuaaggagaauggcccaguccucucccaaguccacacaggggaggugauagcauugcuuucguguaaauuaugu

cortactin mRNA

caggcggcgacggaaucagucccccaaugccuggaaauuccucauuggauuacuguguuuuaaacagaauuucgugaacagecuuuuaucuccaagcggaa agaaagAUGuggaaagcuucagcaggccacgcuguguccaucgcccaggaugacgcggggggccgaugacuggggggccgacccugauuuuugugaaugaug ugagugagaaggagcaaagauggggugccaagacggugcaggggcuccggggcaccaggagcauaucaacauacacaagcugagggagaaugucuuucaaga gcaucagacccuuaaggagaaggaacuugaaacaggaccaaaagcuucccauggcuauggagggaaauuuGGUGUGGAACaaqaccqaauqqauaaquca dendneddeceaedaanancadnedaaacnnneeaadcaendenedcaddnddaenedddecaddddacadddacadad uugaucagucugcuguaggcuuugaauaccaggggaagacugagaagcaugccucccagaaagacuacuccagugguuuuggcggcaaguauggcgugca ggccgaccgaguagacaagagcgcggugggcuucgacuaccaggggcaagacggagaagcacgagucacagagaguuacuccaaagguuucggcggcaaa nacddnancdacraaddacraradnddanaadadcdcccdnnddcnnndadnancraaddcararadaaracdadnccccadaaadacnandndaraadddn AAGACAGUAccugucgaagcugugaccagcaaaacaaguaacaucagagcuaacuuugaaaaccucgcuaaggagaaagagcaggaggacaggcggaagg ucuaugaaagegcagaggeceeggggccacuaueeegcagaggacagcaecuaegaugaguaegagaaegaueugggggaueaeageeguegeeeuguaega ggccgcuucagggagcucgcauucucuuguguucguguugcccucgugcccaucaagugcagucgggaccucccaggacaagcacgaggccucaggucgg cccuguggcggguaggcaggaaggacugucccagacgaggggcuuccucuagagucucacugcuggggaggaggagggcuggccugauggaaguuaaccc ggagcuaagucaccccagagcacaggagcugccaugucagaugggaaaucugccuaugucauaccgugacagcccgcaggaucaggaaacucaucuccuuc endaddadceddaddenddaceadnecednedndeadneddaddeddndnennneeadaaddneacdndaaaandnenedddaenndddneeedd agugcccqugaaqcquguuuuuqcuccu**GAGGUGCAUUUUCUCAUCAUCCUU**qcuuuaccacaaugaqcaaugaqgucqqguuuuauauqcaacuuauug

Figure S14. Nucleotide sequences of aptamers, mRNAs, and target sites for RNA detection. Target sequences for BHQ1-based aptamers are shown in red. Target sequences for DNB-based aptamers are shown in green.

Supplementary Tables

Table 1. Signal-to-background ratios of BHQ1-sulfoCy3 conjugate probes with different linker lengths. Probes $[2 \mu M]$ and A1 aptamer $[30 \mu M]$ in binding buffer (10 mM Tris-HCl, 100 mM KCl, 5 mM MgCl₂, pH 7.6).




Table S2. Signal-to-background ratio of BHQ1-conjugated probes with different fluorophores.

Probes [2 μ M] and A1 aptamer [30 μ M] in binding buffer (10 mM Tris-HCl, 100 mM KCl, 5 mM MgCl₂, pH 7.6).

	∼µ ^O , (o~, + ^N ₈ , <u>Fluorophore</u>
Fluorophore	signal-to- background ratio
sulfoCy3	±€ ^{5™} 10.5
sulfoCy5 (5)	→ 20.2
ATTO465 (S4)	2.4
BODIPY 558/568 (S5) ب ^ٹ ریٹ	
TAMRA (S6)	2.2
NBD-X (S7) ۲۰۰۴	b ^{so,} 3.6
DEAC (S8)	y ^{™a} , 4.4

Table S3. Signal-to-background ratio of DNB-conjugated probes with different fluorophores. Probes [2 μ M] and DNB1 aptamer [30 μ M] in binding buffer (10 mM Tris-HCl, 100 mM KCl, 5 mM MgCl₂, pH 7.6).

	(०~) _n H	Fluoroj	vhore
Fluorophore		n	signal-to- background ratio
TAMRA (6)		2	11.0
DEAC (S9)		2	2.4
Marina Blue (S10)	,ett	2	3
fluorescein (S11)	ŢŢŢŢ	2	1.5
Oregon Green 488 (S12)	Ċ Ţ Ţ	2	1.5
Rhodamine Green (S13)		2	5.7
(S14)	° ~ ~~	NE42 2	52.4
DY (7) 🔥	~~,0~~~~	7	85.5

Table S4. DNA oligonucleotides.

For	in	vitro	selection	of	DNB	aptamer
-----	----	-------	-----------	----	-----	---------

cemplate	GCTAATACGACTCACTATAGGGAATTCCGCGTGTGCACACC-N60-GTCCGTTGGGATCCTCATGG
forward primer for selection	GCTAATACGACTCACTATAGGGAATTCCGCGTGTGCACACC
reverse primer for selection	CCATGAGGATCCGAACGGAC
For evaluation of probe-binding	activity for short versions of DNB aptamer
forward primer for DNB short	GCTAATACGACTCACTATAGTGTGCACACCGTCGACGTG
reverse primer for DNB short	ATGTGCTTGCTTCACCACAT
DNB short mut template1 forward	GTCTCCACACCGTCGACGTGCGGTGCCTTGTGACGGGCACTTG
DNB short mut templatel reverse	CAAGTGCCCGTCACAAGGCACCGCACGTCGACGGTGTGGAGAC
DNB short mut template2 forward	TGCCTTGTGACGGGCACTTGCAATGTGGTGAAGCAACCACAT
DNB short mut template2 reverse	ATGTGGTTGCTTCACCACATTGCAAGTGCCCGTCACAAGGCA
forward primer for DNB short mut	GCTAATACGACTCACTATAGGGTCTCCACACCGTCGACGTG
reverse primer for DNB short mut	ATGTGGTTGCTTCACCACAT

RNA target forward	GCTAATACGACTCACTATAGGGAATTCTCCGTCGACATTAACAAGCTTGGATCCC
RNA target reverse	GGGATCCAAGCTTGTTAATGTCGACGGAGAATTCCCTATAGTGAGTCGTATTAGC
RT1 template forward	GGGATCCAAGCTTGTTTCACCGTCGACGTGCGGTGCCTTGTGACGGGCACTTGCAATGTGGTGTTCGACGGAGAAT TC
RT1 template reverse	GAATTCTCCGTCGAACACCACATTGCAAGTGCCCGTCACAAGGCACCGCACGTCGACGGTGAAACAAGCTTGGATC CC
RT2 template forward	GGGATCCAAGCTTGTTTACCGTCGACGTGCGGTGCCTTGTGACGGGCACTTGCAATGTGGTTTCGACGGAGAATTC
RT2 template reverse	GAATTCTCCGTCGAAACCACATTGCAAGTGCCCGTCACAAGGCACCGCACGTCGACGGTAAACAAGCTTGGATCCC
RT3 template forward	GGGATCCAAGCTTGTTTCCGTCGACGTGCGTGCCTTGTGACGGGCACTTGCAATGTGGTTCGACGGAGAATTC
RT3 template reverse	GAATTCTCCGTCGAACCACATTGCAAGTGCCCCGTCACAAGGCACCGCACGTCGACGGAAACAAGCTTGGATCCC
RT4 template forward	GGGATCCAAGCTTGTTTCGTCGACGTGCGGTGCCTTGTGACGGGCACTTGCAATGTGTTCGACGGAGAATTC
RT4 template reverse	GAATTCTCCGTCGAACACATTGCAAGTGCCCGTCACAAGGCACCGCACGTCGACGAAACAAGCTTGGATCCC
RT5 template forward	GGGATCCAAGCTTGTTTACCGTCGACGTGCGGTGCTGTGACGCACTTGCAATGTGGTTTCGACGGAGAATTC
RT5 template reverse	GAATTCTCCGTCGAAACCACATTGCAAGTGCGTCACAGCACCGCACGTCGACGGTAAACAAGCTTGGATCCC
RT6 template forward	GGGATCCAAGCTTGTTTACCGTCGACGTGCGGTTGTGACACTTGCAATGTGGTTTCGACGGAGAATTC
RT6 template reverse	GAATTCTCCGTCGAAACCACATTGCAAGTGTCACAACCGCACGTCGACGGTAAACAAGCTTGGATCCC
RT7 template forward	GGGATCCAAGCTTGTTTACCGTCGACGTGCGGTGTGACCTTGCAATGTGGTTTCGACGGAGAATTC
RT7 template reverse	GAATTCTCCGTCGAAACCACATTGCAAGGTCACACCGCACGTCGACGGTAAACAAGCTTGGATCCC
forward primer for RT	GCTAATACGACTCACTATAGGGATCCAAGCTTGTTT
reverse primer for RT	GGGAATTCTCCGTCGAA

Table S4-Continued

to cortactin reverse

For preparation	of	DNA	antamore	that	aro	reenoneive	+ 0	DNA	targets	
for preparation	OT	IVINA	aptamers	unau	are	responsive	ιu	IVINA	cargets	

FOI PIEPAIACION OI KNA aptameis	that are responsive to kink targets			
template for BHQ1 binding aptamer to $\beta\text{-}actin$ forward	TAATACGACTCACTATAGGGGGAGCAATGATGGCCTAGATAAATTCGGAGCTTGATCTTCATT			
template for BHQ1 binding aptamer to $\beta\text{-actin}$ reverse	AATGAAGATCAAGCTCCGAATTTATCTAGGCCATCATTGCTCCCCCTATAGTGAGTCGTATTA			
template for DNB binding aptamer to β -actin forward	TAATACGACTCACTATAGGGATAGGAATCCTACCGTCGACGTGCGGTGCTGTGACGCACTTGCAATGTGGTTGACC CATGCC			
template for DNB binding aptamer to β-actin reverse	GGCATGGGTCAACCACATTGCAAGTGCGTCACAGCACCGCACGTCGACGGTAGGATTCCTATCCCTATAGTGAGTC GTATTA			
template for BHQ1 binding aptamer to cortactin forward	TAATACGACTCACTATAGGGTACTGTCTTCTGGCCTAGATAAATTCGGAGCTTAGGCAGAGGA			
template for BHQ1 binding aptamer to cortactin reverse	TCCTCTGCCTAAGCTCCGAATTTATCTAGGCCAGAAGACAGTACCCTATAGTGAGTCGTATTA			
template for DNB binding aptamer to cortactin forward	TAATACGACTCACTATAGGGAAGGATGATGTACCGTCGACGTGCGGTGCTGTGACGCACTTGCAATGTGGTTAATG CACCTC			
template for DNB binding aptamer to cortactin reverse	GAGGTGCATTAACCACATTGCAAGTGCGTCACAGCACCGCACGTCGACGGTACATCATCCTTCCCTATAGTGAGTC GTATTA			
For preparation of aptamer expression plasmids				
insert for BHQ1 binding aptamer to $\beta\text{-actin}$ forward	GATCCCCGGAGCAATGATGGCCTAGATAAATTCGGAGCTTGATCTTCATTTTTTA			

insert for BHQ1 binding aptamer to $\beta\text{-}actin$ reverse	AGCTTAAAAAAATGAAGATCAAGCTCCGAATTTATCTAGGCCATCATTGCTCCGGG
insert for DNB binding aptamer to $\beta\text{-}actin$ forward	CCCCGGAGCAATGATACCGTCGACGTGCGGTGCTGTGACGCACTTGCAATGTGGTTGATCTTCATTTTT
insert for DNB binding aptamer to $\beta\text{-}\mathrm{actin}$ reverse	AAAAATGAAGATCAACCACATTGCAAGTGCGTCACAGCACCGCACGTCGACGGTATCATTGCTCCGGGG
insert for BHQ1 binding aptamer to cortactin forward	GATCCCCTACTGTCTTCTGGCCTAGATAAATTCGGAGCTTAGGCAGAGGATTTTTA
insert for BHQ1 binding aptamer to cortactin reverse	AGCTTAAAAATCCTCTGCCTAAGCTCCGAATTTATCTAGGCCAGAAGACAGTAGGG
insert for DNB binding aptamer to cortactin forward	GATCCCCAAGGATGATGTACCGTCGACGTGCGGTGCTGTGACGCACTTGCAATGTGGTTAATGCACCTCTTTTA

insert for DNB binding aptamer AGCTTAAAAAGAGGTGCATTAACCACATTGCAAGTGCGTCACAGCACCGCACGTCGACGGTACATCATCCTTGGG

Supplementary Movies

Movie S1. Time-lapse multicolor images of β -actin mRNA granules (green and red dots) in live cells. Images were captured every 1 minutes for 7 minutes; playback is at 2 frames per second. Staining of the nuclei with Hoechst 33342 is shown in blue.

Movie S2. Time-lapse multicolor images of β -actin mRNA granules (green and red dots) in live cells. Images were captured every 1 minutes for 15 minutes; playback is at 2 frames per second. Staining of the nuclei with Hoechst 33342 is shown in blue.

Movie S3. Time-lapse multicolor images of β -actin (red dots) and cortactin (green dots) mRNA granules in live cells. Images were captured every 30 seconds for 15 minutes; playback is at 2 frames per second. Staining of the nuclei with Hoechst 33342 is shown in blue.

Movie S4. Time-lapse multicolor images of β -actin (red dots) and cortactin (green dots) mRNA granules in live cells. Images were captured every 30 seconds for 5 minutes; playback is at 2 frames per second. Staining of the nuclei with Hoechst 33342 is shown in blue.

Movie S5. Time-lapse multicolor images of β -actin (red dots) and cortactin (green dots) mRNA granules in live cells. Images were captured every 1 minutes for 15 minutes; playback is at 2 frames per second. Staining of the nuclei with Hoechst 33342 is shown in blue.

Movie S6. Time-lapse multicolor images of β -actin (red dots) and cortactin (green dots) mRNA granules in live cells under a cellular stress condition. The cells shown in **Movie S3** were further treated with NaAsO₂ (500 µM). Images were captured every 15 seconds for 6 minutes; playback is at 2 frames per second. Staining of the nuclei with Hoechst 33342 is shown in blue.

Movie S7. Time-lapse multicolor images of β -actin (red dots) and cortactin (green dots) mRNA granules in live cells under cellular stress induced by adding NaAsO₂ (500 μ M). Images were captured every 12 seconds for 10 minutes; playback is at 2 frames per second. Staining of the nuclei with Hoechst 33342 is shown in blue.

Movie S8. Time-lapse multicolor images of β -actin (red dots) and cortactin (green dots) mRNA granules in live cells under cellular stress induced by adding NaAsO₂ (500 μ M). Images were captured every 30 seconds for 13 minutes; playback is at 2 frames per second. Staining of the nuclei with Hoechst 33342 is shown in blue.


Movie S9. Time-lapse images without any aptamers in live cells. Images were captured every 12 seconds for 6 minutes; playback is at 2 frames per second. Staining of the nuclei with Hoechst 33342 is shown in blue.

Supplementary Methods

Chemical Synthesis

General. The solvents and chemicals for chemical syntheses were used as purchased, with no further purification. Synthetic method of probe **1** was described in our previous research^[11]. Methoxytrityl-*N*-dPEG[®]_n-TFP ester reagents were purchased from Quanta BioDesign, Ltd. (Ohio, USA). SulfoCy3-NHS-ester Cy5-NHS-ester and sulfoCy5-NHS ester were purchased from Lumiprobe Co. (Florida, USA). TAMRA-SE was purchased from AAT Bioquest, Inc. (California, USA). ATTO465 NHS was purchased from ATTO-TEC GmbH (Siegen, Germany). DEAC-SE was purchased from AnaSpec, Inc. (California, USA). NDB-X-SE was purchased from Setareh Biotech, LLC. (Oregon, USA). 5-Carboxyfluorescein-*N*-hydroxysuccinimide ester was purchased from Toronto Research Chemicals (Ontario, Canada). BODIPY 558/568 NHS, Marina Blue SE and Oregon Green 488 carboxylic acid were purchased from Thermo Fisher Scientific Inc. (Massachusetts, USA). BHQ-1 amine^[2], Rhodamine Green-5-carboxylic acid^[3], and DY (deSO₃-DY520-XL)^[4] were synthesized according to the previous reports. All other solvents and chemicals were purchased from Wako Pure Chemical Industries, Ltd. (Tokyo, Japan), Watanabe Chemical Industries, Ltd. (Hiroshima, Japan), Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan) or Nacalai Tesque, Inc. (Kyoto, Japan).

High-performance liquid chromatography (HPLC) was performed with Shimadzu Prominence HPLC system. The synthetic molecules were purified by reversed-phase HPLC. HPLC conditions were as follows: GL science Inertsil[®] ODS-3 column (5 μ m, 20 × 100 mm); solvent gradient, A, 0.1% trifluoroacetic acid (TFA) in H₂O; B, 0.1% TFA in acetonitrile with gradient indicated below; flow rate, 4.0 mL/min; detector, 220/254/350/480/550/650 nm. HPLC grade reagents were used. NMR spectra were recorded on Bruker Avance III 600 (600 MHz), or JEOL JNM-ECP300 (300 MHz) NMR systems. High-resolution mass spectra were obtained using a Bruker FT-ICR MS Solarix in ESI mode.




General procedure for synthesis of BHQ1-peg_n-NH₂ intermediates S1-S3.


Reagents and conditions: a) Methoxytrityl-N-dPEG[®]_n-TFP ester, *i*Pr₂NEt, DMSO, rt; b) TFA, rt.

Methoxytrityl-*N*-dPEG[®]_n-TFP ester (15 µmol) was added to a solution of BHQ1 amine (4.75 mg, 10 µmol) and *i*Pr₂NEt (6.80 µL, 40 µmol) in DMSO (50 µL). After stirring for 3 h at room temperature, H₂O (300 µL) and hexane (500 µL) were added to the mixture, and the resulting mixture was centrifuged (21,500 ×g for 10 min). After removal of supernatant, residual solid or oil was washed with H₂O (500 µL). The residue was dried *in vacuo* and used for next step without further purification.

The dried residue was dissolved in TFA (400 μ L). After stirring for 2 h at room temperature, the mixture was dried *in vacuo*. Resulting crude mixture was purified by preparative HPLC.




BHQ1-peg₄-NH₂ (S1). Methoxytrityl-*N*-dPEG[®]₄-TFP ester (10.3 mg, 15 µmol) converted according to the general procedure described above. Purification by HPLC (0–3 min: B, 55%; 3–15 min: B, 55–61% at RT, $t_{\rm R} = 11.9$ min) gave **S1** as a TFA salt (60% yield). ¹H-NMR (600 MHz, DMSO- d_6) δ : 7.95–7.92 (2H, m), 7.79 (2H, d, J = 9.0 Hz), 7.76 (1H, d, J = 7.8 Hz), 7.71 (3H, brs), 7.70–7.67 (1H, m), 7.51 (1H, d, J = 0.6 Hz), 7.29 (1H, s), 6.85 (2H, d, J = 9.0 Hz), 3.92 (3H, s), 3.62 (2H, t, J = 6.6 Hz), 3.58 (2H, t, J = 4.8 Hz), 3.57–3.52 (4H, m), 3.51–3.46 (10H, m), 3.13 (2H, q, J = 6.6 Hz), 3.06 (3H, s), 3.00–2.94 (2H, m), 2.63 (3H, s), 2.54 (3H, s), 2.34 (2H, t, J = 6.6 Hz), 1.72 (2H, quint, J = 7.2 Hz). ¹³C-NMR (150 MHz, DMSO- d_6) δ : 170.02, 157.60, 157.40, 154.25, 151.68, 150.04, 146.29, 144.60, 143.43, 142.53, 142.19, 133.81, 132.12, 125.39, 124.18, 119.98, 118.39, 111.36, 99.10, 69.622, 69.616, 69.58, 69.53, 69.50, 69.42, 66.77, 66.54, 55.85, 49.30, 38.53, 38.21, 36.12, 36.07, 26.44, 20.58, 16.17. MS (ESI) calculated for C₃₆H₅₁N₈O₈ [M+H]⁺ 723.3824, observed 723.3821.




BHQ1-peg₈-NH₂ (S2). Methoxytrityl-*N*-dPEG[®]₈-TFP ester (12.9 mg, 15 µmol) converted according to the general procedure described above. Purification by HPLC (0–3 min: B, 55%; 3–23 min: B, 55–65% at RT, $t_{\rm R} = 20.6$ min) gave **S2** as a TFA salt (57% yield). ¹H-NMR (600 MHz, DMSO- d_6) δ : 7.95–7.93 (1H, m), 7.92 (1H, t, J = 6.0 Hz), 7.90 (2H, d, J = 9.6 Hz), 7.76 (1H, d, J = 8.4 Hz), 7.71 (3H, brs), 7.70–7.67 (1H, m), 7.51 (1H, d, J = 0.6 Hz), 7.29 (1H, s), 6.85 (2H, d, J = 9.6 Hz), 3.92 (3H, s), 3.62 (2H, t, J = 6.6 Hz), 3.59 (2H, t, J = 4.8 Hz), 3.57–3.46 (30H, m), 3.13 (2H, q, J = 6.6 Hz), 3.06 (3H, s), 2.97 (2H, q, J = 6.0 Hz), 2.63 (3H, d, J = 0.6 Hz), 2.54 (3H, s), 2.34 (2H, t, J = 6.6

Hz), 1.72 (2H, quint, J = 7.2 Hz). ¹³C-NMR (150 MHz, DMSO- d_6) δ : 169.99, 154.25, 151.68, 150.02, 146.29, 144.62, 143.43, 142.52, 142.19, 133.81, 132.12, 125.39, 124.18, 119.98, 118.38, 111.35, 99.09, 69.65, 69.63, 69.61, 69.58, 69.55, 69.51, 69.43, 66.79, 66.56, 55.84, 49.30, 39.97, 38.20, 36.12, 36.11, 26.44, 20.58, 16.16. MS (ESI) calculated for C₄₄H₆₇N₈O₁₂ [M+H]⁺ 899.4873, observed 899.4873.




BHQ1-peg₁₂-NH₂ (**S3**). Methoxytrityl-*N*-dPEG[®]₁₂-TFP ester (15.6 mg, 15 μmol) converted according to the general procedure described above. Purification by HPLC (0–3 min: B, 60%; 3–17 min: B, 60–67% at RT, $t_R = 14.9$ min) gave **S3** as a TFA salt (49% yield). ¹H-NMR (600 MHz, DMSO- d_6) δ: 7.94–7.93 (1H, m), 7.92 (1H, t, J = 6.0 Hz), 7.90 (2H, d, J = 9.0 Hz), 7.76 (1H, d, J = 7.8 Hz), 7.73 (3H, brs), 7.70–7.67 (1H, m), 7.51 (1H, d, J = 0.6 Hz), 7.29 (1H, s), 6.85 (2H, d, J = 9.0 Hz), 3.92 (3H, s), 3.62 (2H, t, J = 6.6 Hz), 3.59 (2H, t, J = 5.4 Hz), 3.58–3.54 (4H, m), 3.52–3.47 (42H, m), 3.13 (2H, q, J = 6.6 Hz), 1.72 (2H, quint, J = 7.2 Hz). ¹³C-NMR (150 MHz, DMSO- d_6) δ: 169.99, 157.83, 157.62, 154.26, 151.68, 150.02, 146.30, 144.62, 143.43, 142.51, 142.19, 133.81, 132.13, 125.39, 124.17, 119.98, 118.39, 111.36, 99.08, 69.65, 69.64, 69.62, 69.59, 69.56, 69.52, 69.44, 66.80, 66.56, 55.84, 49.30, 43.67, 38.54, 38.20, 36.13, 36.11, 26.44, 20.58, 16.16. MS (ESI) calculated for C₅₂H₈₃N₈NaO₁₆ [M+H+Na]²⁺ 549.2907, observed 549.2908.

General procedure for synthesis of BHQ1-fluorophore conjugated probes 2-5, 8, S4-S8.




Reagents and conditions: a) fluorophore-NHS ester, *i*Pr₂NEt, DMSO, rt.


Fluorophore-NHS ester (1.1–1.5 eq.) was added to a solution of BHQ1-peg_n-NH₂ (1 eq.) and iPr_2NEt (4 eq.) in DMSO (20 µL). After stirring for 3–12 h at room temperature, the mixture was diluted with acetonitrile/H₂O/TFA (600 µL, 47.5:47.5:5 solution) and the mixture was purified by preparative HPLC.




BHQ1-peg₈-sulfoCy3 (2). BHQ1-peg₈-NH₂ (**S2**) (0.50 μ mol) and sulfoCy3-NHS (0.551 mg, 0.75 μ mol) were converted according to the general procedure described above. Purification by HPLC (0–3 min: B, 45%; 3–20.5 min: B, 45–58% at RT, $t_{\rm R} = 22.0$ min) gave **2** (22% yield). MS (ESI) calculated for C₇₄H₁₀₀N₁₀Na₂O₁₉S₂ [M+2Na]²⁺ 771.3196, observed 771.3183.




BHQ1-peg₁₂-sulfoCy3 (3). BHQ1-peg₁₂-NH₂ (**S3**) (0.50 µmol) and sulfoCy3-NHS (0.551 mg, 0.75 µmol) were converted according to the general procedure described above. Purification by HPLC (0–3 min: B, 45%; 3–28 min: B, 45–55% at RT, $t_{\rm R} = 24.9$ min) gave **3** (16% yield). MS (ESI) calculated for C₈₂H₁₁₆N₁₀Na₂O₂₃S₂ [M+2Na]²⁺ 859.3720, observed 859.3703.




BHQ1-peg₄-sulfoCy3 (4). BHQ1-peg₄-NH₂ (**S1**) (0.25 μ mol) and sulfoCy3-NHS (0.276 mg, 0.38 μ mol) were converted according to the general procedure described above. Purification by HPLC (0–3 min: B, 50%; 3–23 min: B, 50–70% at RT, $t_{\rm R}$ = 18.2 min) gave **4** (19% yield). MS (ESI) calculated for C₆₆H₈₄N₁₀Na₂O₁₅S₂ [M+2Na]²⁺ 683.2672, observed 683.2670.




BHQ1-peg₈-sulfoCy5 (5). BHQ1-peg₈-NH₂ (S2) (0.25 μmol) and sulfoCy5-NHS (0.248 mg, 0.33 μmol) were converted according to the general procedure described above. Purification by HPLC (0–3 min: B, 45%; 3–21 min: B, 45–61% at RT, $t_R = 19.2$ min) gave 5 (79% yield). ¹H-NMR (600 MHz, DMSO- d_6) δ: 8.34 (2H, dd, 13.2, 13.2), 7.94–7.90 (2H, m), 7.82–7.78 (1H, m), 7.81 (1H, s), 7.78 (2H, d, J = 9.0 Hz), 7.76 (1H, d, J = 8.4 Hz), 7.69–7.66 (1H, m), 7.66–7.62 (2H, m), 7.50 (1H, d, J = 0.6 Hz), 7.33–7.28 (2H, m), 7.28 (1H, s), 6.84 (2H, d, J = 9.0 Hz), 6.55 (1H, dd, J = 13.2, 13.2 Hz), 6.29 (1H, d, J = 13.2 Hz), 6.24 (1H, d, J = 13.2 Hz), 4.06 (2H, t, J = 7.2 Hz), 3.91 (3H, s), 3.61 (2H, t, J = 6.6 Hz), 3.58 (3H, s), 3.53–3.46 (32H, m), 3.40–3.30 (16H, m) 3.19–3.11 (4H, m), 3.05 (3H, s), 2.62 (3H, s), 2.33 (2H, t, J = 6.6 Hz), 2.05 (2H, t, J = 7.2 Hz), 1.75–1.65 (2H, m), 1.53 (2H, quint, J = 7.2 Hz), 1.37–1.29 (2H, m), 1.28–1.23 (2H, m). MS (ESI) calculated for C₇₆H₁₀₂N₁₀NaO₁₉S₂ [M+Na]²⁺ 784.3274, observed 784.3270. Quantum yield (φ): 0.31%. Molar extinction coefficient (ε): 271000.




BHQ1-peg₈-Cy5 (8). BHQ1-peg₈-NH₂ (**S2**) (0.50 µmol) and Cy5-NHS (0.370 mg, 0.60 µmol) were converted according to the general procedure described above. Purification by HPLC (0–3 min: B, 55%; 3–33 min: B, 55–80% at RT, $t_{\rm R}$ = 29.1 min) gave **5** (76% yield). MS (ESI) calculated for C₇₆H₁₀₃N₁₀NaO₁₃ [M+Na]²⁺ 693.3796, observed 693.3791. Quantum yield (φ): 0.29%. Molar extinction coefficient (ε): 250000.




BHQ1-peg₈-ATTO465 (S4). BHQ1-peg₈-NH₂ (S2) (0.50 µmol) and ATTO465-NHS (0.271 mg, 0.55 µmol) were converted according to the general procedure described above. Purification by HPLC (0–3 min: B, 50%; 3–23 min: B, 50–60% at RT, $t_{\rm R} = 21.2$ min) gave S4 (83% yield). MS (ESI) calculated for C₆₁H₈₃N₁₁O₁₃ [M+H]²⁺ 588.8080, observed 588.8081.




BHQ1-peg₈-BODIPY 558/568 (S5). BHQ1-peg₈-NH₂ (**S2**) (0.50 μmol) and BODIPY 558/568-NHS (0.266 mg, 0.60 μmol) were converted according to the general procedure described above. Purification by HPLC (0–3 min: B,70%; 3–23 min: B, 70–78% at RT, $t_{\rm R}$ = 20.1 min) gave **S5** (4.7% yield). MS (ESI) calculated for C₆₀H₇₇BF₂N₁₀O₁₃S [M+H]²⁺ 613.2721, observed 613.2720.



BHQ1-peg₈-TAMRA (S6). BHQ1-peg₈-NH₂ (S2) (0.50 µmol) and TAMRA-SE (0.271 mg, 0.55 µmol) were converted according to the general procedure described above. Purification by HPLC (0–3 min: B, 50%; 3–23 min: B, 50–60% at RT, $t_{\rm R} = 23.7$ min) gave S6 (quant.). MS (ESI) calculated for C₆₉H₈₇N₁₀NaO₁₆ [M+Na]²⁺ 667.3094, observed 667.3090.




BHQ1-peg₈-NBD-X (**S7**). BHQ1-peg₈-NH₂ (**S2**) (0.25 μ mol) and NBD-X-SE (0.147 mg, 0.38 μ mol) were converted according to the general procedure described above. Purification by HPLC (0–3 min: B, 60%; 3–28 min: B, 60–85% at RT, $t_{\rm R}$ = 26.5 min) gave **S7** (14% yield). MS (ESI) calculated for C₅₆H₈₀N₁₂O₁₆ [M+2H]²⁺ 588.2902, observed 588.2904.




BHQ1-peg₈-DEAC (S8). BHQ1-peg₈-NH₂ (**S2**) (0.25 μ mol) and DEAC-SE (0.134 mg, 0.38 μ mol) were converted according to the general procedure described above. Purification by HPLC (0–3 min: B, 70%; 3–27 min: B, 70–86% at RT, $t_s = 9.54$ min) gave **S7** (12% yield). MS (ESI) calculated for C₅₈H₇₉N₉NaO₁₅ [M+Na]⁺ 1164.5588, observed 1164.5580.

Synthesis of DNB-peg2-fluorophore conjugated probes 6, S9-S14.




Reagents and conditions: a) BocNH-PEG₂-NH₂, *i*Pr₂NEt, CH₂Cl₂, rt; b) 4 M HCl/AcOEt, rt; c) fluorophore-NHS ester, *i*Pr₂NEt, DMSO, rt; d) fluorophore-CO₂H, HATU, HOAt, *i*Pr₂NEt, DMSO, rt.




DNB-peg₂-NH₂ (S15). 2,4-dinitrofluorobenzen (106 µL 0.85 mmol) was added to a solution of BocNH-PEG_n-NH₂ (233 mg, 0.94 mmol) and *i*Pr₂NEt (288 µL 1.7 mmol) in CH₂Cl₂ (5 mL). After stirring for 2 h at room temperature, 0.2 M HCl aq. (20 mL) was added to the mixture, and the resulting mixture was extracted with CH₂Cl₂ (10 mL × 3). The combined organic layer was washed with brine (10 mL), dried over Na₂SO₄, filtered, and evaporated. The residue was purified by silica gel column chromatography using hexane/AcOEt (77:23 to 19:81) as eluent, to give DNB-peg₂-NHBoc (322mg, 92% yield). ¹H-NMR (300 MHz, CDCl₃) δ : 9.15 (1H, d, *J* = 2.8 Hz), 8.82 (1H, brs) 8.29 (1H, dd, *J* = 2.8, 9.3), 6.94 (1H, d, *J* = 9.3), 4.97 (1H, brs), 3.84 (2H, t, *J* = 5.4), 3.75–3.50 (m, 8H), 3.33 (2H, q, *J* = 4.8), 1.43 (9H, s).


DNB-peg₂-NHBoc (322 mg, 0.78 mmol) was dissolved in 4 M HCl/AcOEt (5 mL) and stirred at room temperature for 3 h. The resulting solid was collected by filtration to give **S15** as a HCl salt (236 mg, 86% yield). ¹H-NMR (300 MHz, DMSO- d_6) δ : 8.87 (1H, d, J = 2.4 Hz), 8.87–8.83 (1H, m), 8.28 (1H, dd, J = 2.4, 9.6 Hz), 7.97 (3H, brs), 7.30 (1H, d, J = 9.6 Hz), 3.75–3.66 (4H, m), 3.65–3.55 (6H, m), 2.94 (2H, q, J = 5.4 Hz). MS (ESI) calculated for C₁₂H₁₉N₄O₆ [M+H]⁺ 315.1299, observed 315.1299.




NB-peg₂-TAMRA (6). TAMRA-SE (0.158 mg, 0.30 µmol) was added to a solution of DNB-peg₂-NH₂ (**S15**) (0.0875 mg, 0.25 µmol) and *i*Pr₂NEt (0.170 µL 1.0 µmol) in DMSO (20 µL). After stirring for 12 h at room temperature, the mixture was diluted with acetonitrile/H₂O/TFA (600 µL, 47.5:47.5:5 solution) and the mixture was purified by preparative HPLC (0–3 min: B, 40%; 3–21 min: B, 40–49% at RT, $t_{\rm R} = 20.9$ min) gave **6** (84% yield). ¹H-NMR (600 MHz, DMSO- d_6) δ : 13.31 (1H, brs), 8.92–8.87 (1H, m), 8.85 (1H, t, J = 5.4 Hz), 8.83 (1H, d, J = 2.4 Hz), 8.63 (1H, brs), 8.26 (1H, d, J = 7.8 Hz), 8.23 (1H, ddd, J = 0.6, 2.4, 9.6 Hz), 7.51 (1H, brs), 7.26 (1H, d, J = 9.6 Hz), 7.23–6.64 (5H, m), 6.53 (1H, m), 3.72 (2H, t, J = 5.4 Hz), 3.65 (2H, t, J = 5.4 Hz), 3.65–3.59 (4H, m), 3.59 (2H, t, J = 6.0 Hz), 3.53–3.45 (2H, m), 3.22 (12H, brs). MS (ESI) calculated for C₃₇H₃₉N₆O₁₀ [M]⁺ 727.2722, observed 727.2714.




DNB-peg₂-DEAC (S9). DEA-SE (0.128 mg, 0.30 µmol) was added to a solution of DNB-peg₂-NH₂ (**S15**) (0.0875 mg, 0.25 µmol) and *i*Pr₂NEt (0.170 µL 1.0 µmol) in DMSO (20 µL). After stirring for 10 h at room temperature, the mixture was diluted with acetonitrile/H₂O/TFA (600 µL, 47.5:47.5:5 solution) and the mixture was purified by preparative HPLC (0–3 min: B, 45%; 3–33 min: B, 45–75% at RT, $t_{\rm R}$ = 32.0 min) gave **S9** (41% yield). MS (ESI) calculated for C₂₆H₃₁N₅NaO₉ [M+Na]⁺ 580.2014, observed 580.2014.




DNB-peg₂-Marina Blue (S10). Marina Blue-SE (0.110 mg, 0.30 µmol) was added to a solution of DNB-peg₂-NH₂ (**S15**) (0.0875 mg, 0.25 µmol) and *i*Pr₂NEt (0.170 µL 1.0 µmol) in DMSO (20 µL). After stirring for 10 h at room temperature, the mixture was diluted with acetonitrile/H₂O/TFA (600 µL, 47.5:47.5:5 solution) and the mixture was purified by preparative HPLC (0–3 min: B, 45%; 3–28 min: B, 45–70% at RT, $t_{\rm R}$ = 18.5 min) gave **S10** (41% yield). MS (ESI) calculated for C₂₄H₂₄F₂N₄NaO₁₀ [M+Na]⁺ 589.1353, observed 589.1353.




DNB-peg₂-fluorescein (S11). 5-Carboxyfluorescein-N-hydroxysuccinimide Ester (0.142 mg, 0.30 μ mol) was added to a solution of DNB-peg₂-NH₂ (**S15**) (0.0875 mg, 0.25 μ mol) and *i*Pr₂NEt (0.170 μ L 1.0 μ mol) in DMSO (20 μ L). After stirring for 10 h at room temperature, the mixture was diluted with acetonitrile/H₂O/TFA (600 μ L, 47.5:47.5:5 solution) and the mixture was purified by preparative HPLC (0–3 min: B, 45%; 3–28 min: B, 45–70% at RT, *t*_R = 20.2 min) gave **S11** (53% yield). MS (ESI) calculated for C₃₃H₂₈N₄NaO₁₂ [M+Na]⁺ 695.1596, observed 695.1594.



DNB-peg₂-Oregon Green 488 (S12). *i*Pr₂NEt (0.170 µL 1.0 µmol) was added to a solution of Oregon Green 488 carboxylic acid (0.124 mg, 0.30 µmol), HATU (0.190 mg, 0.50 µmol), HOAt (0.0681 mg, 0.50 µmol) and DNB-peg₂-NH₂ (**S15**) (0.0875 mg, 0.25 µmol) in DMSO (20 µL). After stirring for 10 h at room temperature, the mixture was diluted with acetonitrile/H₂O/TFA (600 µL, 47.5:47.5:5 solution) and the mixture was purified by preparative HPLC (0–3 min: B, 45%; 3–28 min: B, 45–70% at RT, $t_{\rm R} = 21.9$ min) gave **S12** (25% yield). MS (ESI) calculated for C₃₃H₂₆F₂N₄NaO₁₂ [M+Na]⁺ 731.1407, observed 731.1406.




DNB-peg₂-Rhodamine Green (S13). *i*Pr₂NEt (0.170 µL 1.0 µmol) was added to a solution of Rhodamine Green-5-carboxylic acid (0.147 mg, 0.30 µmol), HATU (0.190 mg, 0.50 µmol), HOAt (0.0681 mg, 0.50 µmol) and DNB-peg₂-NH₂ (**S15**) (0.0875 mg, 0.25 µmol) in DMSO (20 µL). After stirring for 10 h at room temperature, the mixture was diluted with acetonitrile/H₂O/TFA (600 µL, 47.5:47.5:5 solution) and the mixture was purified by preparative HPLC (0–3 min: B, 40%; 3–28 min: B, 40–65% at RT, $t_{\rm R} = 11.9$ min) gave **S13** (22% yield). MS (ESI) calculated for C₃₃H₃₁N₆O₁₀ [M]⁺ 671.2096, observed 671.2093.




DNB-peg₂-DY (S14). *i*Pr₂NEt (0.170 µL 1.0 µmol) was added to a solution of deSO₃-DY520-XL (0.163 mg, 0.30 µmol), HATU (0.190 mg, 0.50 µmol), HOAt (0.0681 mg, 0.50 µmol) and DNB-peg₂-NH₂ (**S15**) (0.0875 mg, 0.25 µmol) in DMSO (20 µL). After stirring for 16.5 h at room temperature, the mixture was diluted with acetonitrile/H₂O/TFA (600 µL, 47.5:47.5:5 solution) and the mixture was purified by preparative HPLC (0–3 min: B, 50%; 3–23 min: B, 50–60% at RT, $t_{\rm R} = 15.0$ min) gave **S14** (62% yield).


Synthesis of DNB-peg7-DY conjugated probe 7.



Reagents and conditions: a) BocNH-PEG₇-NH₂, *i*Pr₂NEt, CH₃CN, rt; b) 4 M HCl/AcOEt/AcOEt (3:1), rt; c) deSO₃-DY520-XL, HATU, HOAt, *i*Pr₂NEt, DMSO, rt.



DNB-peg₇-**NH**₂ (**S17**). 2,4-dinitrofluorobenzen (0.628 µL 5.0 µmol) was added to a solution of BocNH-PEG_n-NH₂ (2.81 mg, 6.0 µmol) and *i*Pr₂NEt (1.70 µL 10 µmol) in CH₃CN (50 µL). After stirring for 2 h at room temperature, 0.2 M HCl aq. (200 µL) was added to the mixture, and the resulting mixture was extracted with CH₂Cl₂ (200 µL × 4). The combined organic layer was washed with brine (100 µL), dried over Na₂SO₄, filtered, and evaporated. The residue was dissolved in 4 M HCl/AOEt (300 µL) / AcOEt (100 µL) and stirred at room temperature for 2 h. Hexane (2 mL) was added to the mixture, and the resulting mixture was centrifuged (21,500 ×g for 10 min). After removal of supernatant, residual oil was used for next step without further purification. to give **S17** as a HCl salt. ¹H-NMR (600 MHz, DMSO-*d*₆) δ : 8.87 (1H, d, *J* = 3.0 Hz), 8.86–8.84 (1H, m), 8.27 (1H, ddd, *J* = 0.6, 3.0, 9.6 Hz), 7.74 (3H, brs), 7.29 (1H, d, *J* = 9.6 Hz), 3.71–3.65 (4H, m), 3.60–3.47 (26H, m), 2.97 (2H, t, *J* = 5.4 Hz). ¹³C-NMR (150 MHz, DMSO-*d*₆) δ : 148.29, 134.81, 129.79, 129.58, 123.47, 115.60, 69.70, 69.69. 69.65, 69.64, 69.62, 69.55, 69.51, 42.57, 38.53. MS (ESI) calculated for C₂₂H₃₉N₄O₁₁ [M+H]⁺ 535.2610, observed 535.2607.



DNB-peg7-DY (7). *i*Pr2NEt (0.170 µL 1.0 µmol) was added to a solution of deSO3-DY520-XL (0.163 mg, 0.30 µmol), HATU (0.190 mg, 0.50 µmol), HOAt (0.0681 mg, 0.50 µmol) and DNB-peg₂-NH₂ (**S15**) (0.0875 mg, 0.25 μ mol) in DMSO (20 μ L). After stirring for 16.5 h at room temperature, the mixture was diluted with acetonitrile/H2O/TFA (600 µL, 47.5:47.5:5 solution) and the mixture was purified by preparative HPLC (0–3 min: B, 50%; 3–23 min: B, 50–60% at RT, $t_R =$ 15.7 min) gave **S14** as a TFA salt (62% yield). ¹H-NMR (600 MHz, DMSO- d_6) δ : 8.87–8.82 (4H, m), 8.25 (1H, ddd J = 0.6, 2.4, 9.6 Hz), 8.21 (1H, s), 8.16 (2H, d, J = 9.6 Hz), 7.85–7.81 (2H, m), 7.68 (1H, d, J = 16.2 Hz), 7.54 (1H, d, J = 9.0 Hz), 7.27 (1H, d, J = 9.6 Hz), 6.80 (1H, dd, J = 2.4, 9.0 Hz), 6.60 (1H, d, J = 2.4 Hz), 6.53 (1H, brs), 4.45 (2H, t, J = 7.2 Hz), 3.70–3.63 (4H, m), 3.59–3.56 (2H, m), 3.54–3.44 (26H, m), 3.17 (2H, q, *J* = 6.0 Hz), 2.07 (2H, t, *J* = 7.2 Hz), 1.89 (2H, quint, *J* = 7.2 Hz), 1.53 (2H, quint, J = 7.2 Hz), 1.28–1.18 (4H, m), 1.15 (6H, t, J = 7.2 Hz). ¹³C-NMR (150 MHz, DMSO-*d*₆) δ: 171.83, 159.48, 156.22, 153.22, 151.90, 148.26, 145.32, 143.83, 136.87, 134.78, 130.65, 129,76, 129.53, 123.43, 123.19, 122.49, 115.55, 113.52, 109.95, 108.25, 96.12, 69.69, 69.65, 69.64, 69.63 69.60, 69.44, 69.03, 59.20, 44.27, 38.3234.74, 30.12, 24.86, 24.35, 12.26. MS (ESI) calculated for $C_{48}H_{67}N_6O_{14}$ [M]⁺ 951.4710, observed 951.4707. Quantum yield (φ): 6.7%. Molar extinction coefficient (ϵ): 49244.

General procedure

UV-vis absorption spectra in a binding buffer (10 mM Tris-HCl, 100 mM KCl, 5 mM MgCl₂, pH 7.6) were measured using a U-3010 spectrophotometer (Hitachi High-Technologies Corp.). Fluorescence spectra were recorded using an LS 55 Fluorescence spectrometer (PerkinElmer Co., Ltd.). The live-cell and fixed cell imaging were performed using a CellVoyagerTM CV1000 Confocal Scanner Box (Yokogawa Electric Corp.), equipped with an ultra-sensitive EMCCD C_9100 13 camera (512 × 512 pixels) and an Olympus UPLSAPO 60XO 1.35 NA oil objective. The excitation laser wavelength and emission filter were as follows: excitation 405 and emission BP477/60 nm for detection of Hoechst signal; excitation 488 and emission BP617/73 nm for detection of probes **5** (sulfoCy5) and **8** (Cy5). The images were analyzed using CellVoyagerTM CV1000 measurement software and NIH ImageJ, and presented as maximum-intensity projection (MIP) or the best focus single plane.

The BHQ1-binding aptamer A1 was prepared as described in a previous report^[1,5]. The dsDNAs for T7 transcription of DNB-binding aptamer were PCR amplified using corresponding pUC19 plasmids as a template, with primer sets described in **Table S4** (see Method for *in vitro* selection procedures for DNB-binding aptamer). The dsDNA templates for the DNB-binding aptamer and DNB-short aptamers were prepared by PCR, amplified using pUC19-DNB1 plasmid as a template, with the primer set described in **Table S4**. The dsDNA template for the mutated version of DNB-short aptamer (DNB short mut) was prepared by PCR, amplified using dsDNA from annealing of two synthetic ssDNAs (**Table S4**) as a template, with the primer set described in **Table S4**. The dsDNA templates for the RNA aptamers and target RNAs were prepared by annealing of two synthetic ssDNAs (**Table S4**). RNAs for *in vitro* experiments were prepared by *in vitro* transcription reaction at 37°C for 12 h using T7 MegaScript kit (invitrogen), and purified using an NAP-5 column to remove unincorporated NTPs. The dsDNA templates of the RNA aptamers that were responsive to β -actin or cortactin were prepared by annealing two synthetic ssDNAs (**Table S4**). The dsDNAs were subcloned into the *Bgl* II and *Hind* III sites in pSuper.neo vector. Synthetic ssDNAs were purchased from Thermo Fisher Scientific Inc. (Massachusetts, USA).

Fluorescence measurement. Fluorescence spectra of each probe (2 μM) were obtained in binding buffer (10 mM Tris-HCl, 100 mM KCl, 5 mM MgCl₂, pH 7.6), in the absence or presence of RNA aptamer and target RNA (annealed before mixing with probe). The excitation wavelengths and fluorescence emissions (Ex/Em) monitored for each conjugates were 520/540-700 nm for probes 1–4, 6, S5, and S6; 620/640-800 nm for probe 5; 430/450-600 nm for probes S4 and S7; 390/420-600 nm for probes S8–S10; 480/500-650 nm for probes S11–S13; and 500/550-800 nm for probes 7 and S14.

In vitro selection procedures for DNB binding aptamer (Figure S7). BHQ1-immobilized affinity resin was prepared as described in a previous report^[1,5]. DNB-peg₂-NH₂ (S15) was immobilized to EAH Sepharose[™] 4B resin, linked by diglycolic acid to give DNB-immobilized affinity resin. The dsDNA library for templates of the 1st round RNA pool was prepared by Klenow reaction of template and reverse primer (Table S4). The dsDNA template was converted to an RNA pool by in vitro transcription reaction at 37°C for 12 h, using T7 MegaScript kit (Invitrogen), and purified using an NAP-5 column. The resulting RNA pool was annealed in binding buffer (200 µL for 1st round, 100 µL for 2nd and additional rounds, 10 mM Tris-HCl, 100 mM KCl, pH 7.6). After addition of 1 µL of MgCl₂ solution (final concentration, 5 mM), the solution was incubated on the BHQ1-immobilized affinity resin for 15 minutes at 4°C. The unbound RNA species were drained, and the pass-through faction was incubated on the DNB-immobilized affinity resin for 30 minutes at 4°C. The unbound RNA species were drained, and the resin was washed 8 times with a binding buffer to remove the non-binding species. Bound RNA species were eluted using binding buffer saturated with free DNB-peg₂-NH₂ solution (1 mM), 3 times for 10 min each. The eluted fractions were pooled and precipitated with ethanol. The selected RNAs were reverse-transcribed using ReverTra Ace[®] (Toyobo Co., Ltd.), and the resulting cDNA was PCR-amplified with the forward and the reverse primers in **Table S4**. The DNA templates were transcribed *in vitro*, and the resulting RNAs were subjected to the next round of selection. After eight rounds of selection, enriched RNAs were reverse-transcribed, and converted to dsDNA by PCR. The resulting DNAs were ligated into pUC19 at the EcoRI and BamHI sites, and transformed to stellar competent cells of an E. coli strain (Takara Bio Inc.). The resulting clones were isolated and sequenced.

Kd determination. Probe 6 (2 μ M) was dissolved in the binding buffer in the presence of RNA (0, 1, 3, 10, 30 or 100 μ M), and fluorescence intensity was measured using an MTP-800 multi microplate reader (CORONA) with an Ex/Em = 550/610 nm filter set. The *K*d values of DNB1-DNB4 were estimated from the fluorescence titration data, using the equation:

 $Fobs = A((([6]_{T} + [aptamer]_{T} + Kd) - (([6]_{T} + [aptamer]_{T} + Kd)^{2} - 4[6]_{T}[aptamer]_{T})^{1/2})/2[6]_{T})$

where *A* is the increase in fluorescence at saturating DNB1 concentration (F max - F min), *K*d is the dissociation constant, and $[6]_T$ and $[aptamer]_T$ are the total concentrations of probe 6 and aptamer DNB1-DNB4, respectively.

Cell culture and DNA transfection. HeLa cells were maintained in Dulbecco's modified Eagle medium (Gibco[®]), supplemented with 100 units/mL penicillin, 100 μ g/mL streptomycin sulfate, and 10% (v/v) fetal bovine serum (Biowest), at 37°C and 5% CO₂ in a humidified incubator. The cells


were transfected with the aptamer expression plasmids using FuGENE HD transfection reagent (Promega), according to the manufacturer's protocol. To induce stress, 0.05 M sodium arsenite solution (Sigma-Aldrich Co., LLC) was added (final concentration, 500 μ M). The stress-induced cells were used immediately for live-cell experiments, and after 1 h incubation for fixed-cell experiments.


Fixed cell imaging. HeLa cells were seeded on a Poly-D-lysine coated glass-bottom ViewPlate[®]-96F microplate (PerkinElmer, Inc.) at $3.0-5.0 \times 10^3$ cells per well. After day 1, cells were fixed with 4% paraformaldehyde solution (Muto Pure Chemicals Co., Ltd) at room temperature for 15 min, washed twice with PBS, and then permeabilized with methanol overnight at -20°C. The cells were soaked in 2× SSC buffer (300 mM NaCl, 30 mM sodium citrate, pH 7.0) containing 50% formamide at 50°C for 15 min. The cells were then incubated at 4°C for 24 h with a 2× SSC buffer (50 µL), containing 10 µM aptamers, 10% dextran sulfate, 0.02% RNase-free BSA, and 40 µg *E. coli* tRNA. Excess aptamers were washed out twice with 2× SSC buffer. The cells were then treated at 4°C for 5 min with probes **5** (2 µM) and **7** (2 µM), and DAPI (2 µg/mL) in 2× SSC buffer (30 µL). Excess probes were washed out with 2× SSC buffer, and the cells were observed on CV1000 microscope. The cell images were taken with a vertical range of 2 µm, and each image stack was then projected onto a single plane.

Live-cell imaging. On day 0, HeLa cells were seeded on a 12-well plate at 5.0×10^4 cells per well. On day 1, the cells were transfected with pSuper.neo vectors encoding each aptamer. On day 2, the cells were detached with 0.25% trypsin, and re-seeded at 1.0×10^4 cells per cell on CELLVIEWTM glass bottom cell culture dishes (Greiner Bio One International GmbH, 4 compartments, 35 mm, pre-coated with advanced TC) in the complete growth medium, then incubated at 37° C for 10 min in a humidified 5% CO₂ incubator. After the cells attached to the plate, they were stained with probes **7** (5 µM) and **8** (5 µM), and Hoechst 33342 (1 µg/mL) in the complete growth medium (100 µL), and incubated at 37° C for 5 min in a humidified 5% CO₂ incubator. The medium was then changed to Medium 199, Hank's Balanced Salts (Gibco[®]), and the cells were observed on a CV1000 microscope. Live-cell images were collected as 4 µm of vertical z-stack range (~11 focal planes), and presented as MIP. Time-lapse images were taken at 0-30 s intervals for up to 10 minutes.


Supplementary References

- (1) Murata, A.; Sato, S.; Kawazoe, Y.; Uesugi, M. Chem. Commun. 2011, 47, 4712–4714.
- (2) Jing, C.; Cornish, V. W. ACS Chem. Biol. 2013, 8, 1704–1712.
- (3) Grimm, J. B.; Lavis, L. D. Org. Lett. 2011, 13, 6354–6357.
- (4) Peter Czerney, Matthias Wenzel, Bernd Schweder, F. L. US20040260093A1, 2004.
- (5) Sato, S.; Yatsuzuka, K.; Katsuda, Y.; Uesugi, M. *Methods Mol. Biol.* **2018**, *1649*, 305–318.







.




BHQ1-peg4;1H




BHQ1-peg4;13C






BHQ1-peg8;13C




BHQ1-peg12;1H


-




BHQ1-peg12;13C




BHQ1-sulfoCy5;1H




DNB-TAMRA;1H



DNB-peg7;1H



DNB-DY;1H



DNB-DY;13C

